Long-term antiviral treatment for recurrent hepatitis C after liver transplantation
| Autor: | Antonietta D'Errico-Grigioni, Maria Cristina Morelli, Matteo Ravaioli, Paolo Di Gioia, Alessandro Cucchetti, Mariarosa Tamè, Valentina Rosa Bertuzzo, Massimo Del Gaudio, Antonio Daniele Pinna, Alessandro Dazzi, Matteo Cescon, Giorgio Ercolani, Pietro Andreone, Stefania Lorenzini |
|---|---|
| Přispěvatelé: | Bertuzzo V.R., Cescon M., Morelli M.C., Di Gioia P., Tamè M., Lorenzini S., Andreone P., Ercolani G., Del Gaudio M., Ravaioli M., Cucchetti A., Dazzi A., D'Errico-Grigioni A., Pinna A.D. |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Interferon alpha-2 Liver transplantation Antiviral Agents Group A Gastroenterology Group B chemistry.chemical_compound INTERFERON THERAPY Recurrence Internal medicine Ribavirin medicine Humans Survival rate Aged Retrospective Studies Hepatitis Hepatology business.industry Interferon-alpha HEPATITIS C VIRUS LIVER TRANSPLANTATION Retrospective cohort study Hepatitis C Middle Aged medicine.disease Recombinant Proteins Liver Transplantation Surgery Survival Rate Liver chemistry Disease Progression RNA Viral Drug Therapy Combination Female business Immunosuppressive Agents |
| Zdroj: | Digestive and Liver Disease. 44:861-867 |
| ISSN: | 1590-8658 |
| Popis: | Background and aims The management of patients treated for hepatitis C recurrence after liver transplantation and not achieving virological response following treatment with interferon plus ribavirin is controversial. Methods A retrospective analysis of the outcomes of 70 patients non-responders to antiviral treatment after liver transplantation was performed. Twenty-one patients (30.0%; Group A) were treated for ≤12 months and 49 (70.0%; Group B) for more than 12 months. Results The 2 groups were comparable for main demographic, clinical and pathological variables. Median duration of antiviral treatment was 8.2 months in Group A and 33.4 months in Group B. No patient achieved a complete virological response. The 5-year patient hepatitis C-related survival rate was 49.2% in Group A and 88.3% in Group B (P = 0.002), while the 5-year graft survival rate was 49.2% in Group A and 85.9% in Group B (P = 0.007). The median yearly fibrosis progression rate was 1.21 per year in Group A and 0.40 per year in Group B (P = 0.001). Conclusions Prolonged antiviral treatment showed an overall beneficial effect in transplanted patients with a recurrent hepatitis C infection and not responding to conventional therapy. The treatment should be continued as long as it is permitted, in order to improve clinical and histological outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect